Apellis Pharmaceuticals will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference scheduled for March 2, 2026. The biopharmaceutical company plans to discuss its complement-targeted therapeutic platform during the investor-focused event.
The company's marketed portfolio includes two C3-targeting medicines approved across four disease indications. Apellis' commercial offerings encompass the first approved therapy for geographic atrophy, a leading cause of vision loss in elderly patients, alongside treatments for rare kidney diseases including C3 glomerulopathy and post-infectious glomerulonephritis.
The TD Cowen conference provides a platform for healthcare companies to present clinical and commercial developments to institutional investors and industry analysts. Apellis' participation underscores the company's focus on communicating its complement-focused strategy and approved product applications to the investment community.